Physician profile
Daniel P Stupak
NPI 1669664314
$46,862.63
in general payments reported to CMS, 2019-2025
33 companies · $8,161 in 2025
The $8,161 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,847 · 2020: $5,244 · 2021: $4,474 · 2022: $981 · 2023: $11K · 2024: $11K · 2025: $8,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,175 · Travel and Lodging: $122 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,315.00 |
| Food and Beverage | $10,687.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,175.00 |
| Travel and Lodging | $122.47 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $9,598.31 | 2024-2025 | Voquezna |
| Abbvie INC. | $8,049.22 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $7,158.86 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Allergan, INC. | $5,366.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $5,223.76 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $3,053.78 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,544.31 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $918.88 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Ardelyx, INC. | $869.95 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $685.12 | 2024-2025 | Iqirvo |
| Pfizer INC. | $618.82 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $550.35 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $513.32 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $455.39 | 2021-2024 | Zeposia |
| Genzyme Corporation | $380.10 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $324.92 | 2019-2025 | |
| Lilly USA, LLC | $294.84 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $192.92 | 2023-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $185.04 | 2025 | Rezdiffra |
| Vivus LLC | $140.33 | 2025 | Pancreaze, Qsymia |
| Redhill Biopharma INC. | $137.90 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $130.04 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $128.02 | 2021-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $109.32 | 2019-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $79.57 | 2022-2024 | Dupixent |
| Braintree Laboratories, INC. | $39.58 | 2025 | Suflave, Sutab |
| Mirum Pharmaceuticals, INC. | $22.08 | 2025 | Chenodal, Livmarli, Cholbam |
| Amgen INC. | $20.67 | 2023 | Avsola |
| Intra-Sana Laboratories | $20.30 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novo Nordisk INC | $19.83 | 2025 | Wegovy |
| Exact Sciences Corporation | $19.41 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Stupak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.